Products Categories
| CAS No.: | 2898-12-6 |
|---|---|
| Name: | MEDAZEPAM |
| Article Data: | 49 |
| Molecular Structure: | |
|
|
|
| Formula: | C16H15 Cl N2 |
| Molecular Weight: | 270.762 |
| Synonyms: | 1-Methyl-5-phenyl-7-chloro-2,3-dihydro-1H-1,4-benzodiazepine;7-Chloro-1-methyl-1,3-dihydro-2H-1,4-benzodiazepine;7-Chloro-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine;7-Chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine;7-Chloro-2,3-dihydro-1-methyl-5-phenyl-3H-1,4-benzodiazepine; Ansilan;Medazepam; Mezapam; Narsis; Nobrium; Psiquium; Resmit; Rudotel; Tranko buskas;Tranquilax |
| Density: | 1.18g/cm3 |
| Melting Point: | 95-97° |
| Boiling Point: | 404.4°Cat760mmHg |
| Flash Point: | 198.4°C |
| Solubility: | 10.83mg/L(37 oC) |
| Hazard Symbols: | Xn |
| Risk Codes: | 22 |
| Safety: | Poison by intraperitoneal route. Moderately toxic by ingestion. Experimental reproductive effects. A tranquilizer. When heated to decomposition it emits very toxic fumes of Cl− and NOx. See also DIAZEPAM. |
| PSA: | 15.60000 |
| LogP: | 3.12780 |
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.
Chemistry
Molecular Formula: C16H15ClN2
Molar mass: 270.7567 g/mol
EINECS: 220-783-4
Density: 1.18 g/cm3
Flash Point: 198.4 °C
Index of Refraction: 1.617
Boiling Point: 404.4 °C at 760 mmHg
Vapour Pressure: 9.49E-07 mmHg at 25 °C
Structure of Medazepam (CAS NO.2898-12-6):
XLogP3-AA: 4.4
H-Bond Donor: 0
H-Bond Acceptor: 2
IUPAC Name of Medazepam (CAS NO.2898-12-6): 7-Chloro-1-methyl-5-phenyl-2,3-dihydro-1,4-benzodiazepine
Canonical SMILES: CN1CCN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
InChI: InChI=1S/C16H15ClN2/c1-19-10-9-18-16(12-5-3-2-4-6-12)14-11-13(17)7-8-15(14)19/h2-8,11H,9-10H2,1H3
InChIKey: YLCXGBZIZBEVPZ-UHFFFAOYSA-N
Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| cat | LD50 | oral | 750mg/kg (750mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1109, 1969. | |
| mouse | LD50 | intraperitoneal | 360mg/kg (360mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 185, Pg. 135, 1970. | |
| mouse | LD50 | intravenous | 44mg/kg (44mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 13, Pg. 463, 1971. | |
| mouse | LD50 | oral | 475mg/kg (475mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 24, Pg. 2029, 1974. | |
| mouse | LD50 | subcutaneous | 6750mg/kg (6750mg/kg) | Drugs in Japan Vol. -, Pg. 1164, 1990. | |
| rat | LD50 | intraperitoneal | 239mg/kg (239mg/kg) | Drugs in Japan Vol. -, Pg. 1164, 1990. | |
| rat | LD50 | intravenous | 92mg/kg (92mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 13, Pg. 461, 1971. | |
| rat | LD50 | oral | 900mg/kg (900mg/kg) | "Benzodinzenines," Garattini, S., et al., New York, Raven Press, 1973Vol. -, Pg. 35, 1973. | |
| rat | LD50 | subcutaneous | 2980mg/kg (2980mg/kg) | Drugs in Japan Vol. -, Pg. 1164, 1990. |
Safety Profile
Poison by intraperitoneal route. Moderately toxic by ingestion. Experimental reproductive effects. A tranquilizer. When heated to decomposition it emits very toxic fumes of Cl− and NOx. See also DIAZEPAM.
Specification
Medazepam ,its cas register number is 2898-12-6. It also can be called Raporan ; Rudotel ; Ansilan ; Nobrium and 7-Chloro-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine . Medazepam (CAS NO.2898-12-6)is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties.Benzodiazepine drugs including medazepam increase the inhibitory processes in the cerebral cortex by allosteric modulation of the GABA receptor. It has major active benzodiazepine metabolites which gives it a more prolonged therapeutic effects after administration.